Skip to main content

Table 1 Clinical studies of co-infusion of MSCs with HSCs for hematopoietic recovery after hematopoietic stem/progenitor cell transplantation

From: Pharmacological targeting of bone marrow mesenchymal stromal/stem cells for the treatment of hematological disorders

Number of patients Median age of patients, years (range) HSC donor MSC donor MSC dose (×106/kg) Median time for Neut recovery (range) Median time for Plt recovery (range) Reference
46 44.5 (19–61) HLA-matched sibling HSC donor 1.0, 2.5, or 5.0 Neut >500/μl at day 14 (11–26) Plt >20,000/μl at day 20 (15–36) [26]
7 12 (1–44) HLA-matched sibling in three cases
Unrelated donor in three cases
Cord blood in one case
HLA-matched sibling or HLA-haploidentical donor 1.0 Neut >500/μl at day 12 (10–28) Plt >30,000/μl at day 12 (8–36) [27]
8 7.5 (0.25–16) Cord blood HLA-haploidentical parent 0.9–5.0 Neut >500/μl at day 19 (9–28) Plt >50,000/μl at day 53 (36–98) [28]
  1. HLA human leukocyte antigen, HSC hematopoietic stem/progenitor cell, MSC mesenchymal stromal/stem cell, Neut neutrophil, Plt platelet